Journal of Nuclear Medicine· 2026Q1
Residual 177 Lu Activity Complicates Interpretation of Day 3 SPECT in OPTIMAL-PSMA
- 1citations
- Q1SCImago
- 2026year
Short summary
Residual 177Lu activity from [177Lu]PSMA-597 treatment can interfere with Day 3 SPECT imaging, potentially complicating the interpretation of tumor response in the OPTIMAL-PSMA trial.
AI-generated from the title and abstract; the full text is not read.
Key points
- Residual 177Lu activity from [177Lu]PSMA-597 treatment can be present on Day 3 SPECT.
- This residual activity can interfere with the interpretation of tumor uptake.
- Accurate assessment of treatment response may be complicated by this imaging artifact.
- The reliability of Day 3 SPECT as a secondary endpoint in the OPTIMAL-PSMA trial is questioned.
AI-generated from the title and abstract; the full text is not read.
Abstract
TO THE EDITOR: Khan et al. report on OPTIMAL-PSMA, a randomized phase 2 trial comparing an early-dose intensified [177Lu]PSMA-597 regimen with the standard 6 weekly administrations for metastatic castration-resistant prostate cancer ([1][1]). A mechanistic secondary endpoint of the trial is also
The authors' abstract, as published at the source. Journal of Nuclear Medicine, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Radiology, Nuclear Medicine and Imaging
Radiology, Nuclear Medicine and ImagingMedicine